insights_auto
Kwa nini G1SK34 imeongezeka kwa 3.91%?
Fahamu zaidichevron_right
G1SK34:BVMF
GSK plc
R$ 50.45
arrow_upward
+3.91%(+1.90) Siku 1
16 Okt, 11:16:52 GMT -3 · BRL
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya G1SK34...
Fungua
R$ 50.10
Juu
R$ 50.75
Chini
R$ 50.10
Mtaji wa soko
74.92B
Wastani wa kiasi cha mauzo
214.00
Kiasi cha mauzo ya hisa
152.00
Juu kwa wiki 52
R$ 63.24
Chini kwa wiki 52
R$ 46.15
Hisa za wawekezaji
4.32B
Idadi ya wafanyakazi
elfu 67
Fungua
R$ 50.10
Juu
R$ 50.75
Chini
R$ 50.10
Mtaji wa soko
74.92B
Wastani wa kiasi cha mauzo
214.00
Kiasi cha mauzo ya hisa
152.00
Juu kwa wiki 52
R$ 63.24
Chini kwa wiki 52
R$ 46.15
Hisa za wawekezaji
4.32B
Idadi ya wafanyakazi
elfu 67
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
The Globe and Mail
·
saa 2 zilizopita
UBS Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Chemistry World
·
saa 4 zilizopita
Strikes at GSK’s Belgian sites over plans to cut 1200 jobs
Traders Union
·
saa 6 zilizopita
GSK shares technical analysis: Overbought conditions highlight reversal setup
JournalArta
·
saa 13 zilizopita
GSK Stock Gains 2.89% on Thursday: Full Details
Wasifu
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Kuhusu GSK plc
Afisa Mkuu Mtendaji (CEO)Emma Walmsley | Emma Walmsley
Wafanyakazielfu 66.8
Lilianzishwa27 Des 2000
Makao makuu-
Sekta-
Tovutigsk.com